BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8590897)

  • 21. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.
    MacEwen EG; Kurzman ID; Vail DM; Dubielzig RR; Everlith K; Madewell BR; Rodriguez CO; Phillips B; Zwahlen CH; Obradovich J; Rosenthal RC; Fox LE; Rosenberg M; Henry C; Fidel J
    Clin Cancer Res; 1999 Dec; 5(12):4249-58. PubMed ID: 10632367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protection against lethal pneumococcal septicemia in pigs is associated with decreased levels of interleukin-6 in blood.
    Ziegler-Heitbrock HW; Passlick B; Käfferlein E; Coulie PG; Izbicki JR
    Infect Immun; 1992 Apr; 60(4):1692-4. PubMed ID: 1548092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in interleukin 1 (IL-1), IL-6, tumor necrosis factor and IL-1 receptor antagonist production by human monocytes stimulated with muramyl dipeptide (MDP) and its stearoyl derivative, romurtide.
    Suzuki K; Torii K; Hida S; Hayashi H; Hiyama Y; Oomoto Y; Takii T; Chiba T; Onozaki K
    Immunopharmacology; 1994; 28(1):31-8. PubMed ID: 7928300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Muramyl dipeptide enhances osteoclast formation induced by lipopolysaccharide, IL-1 alpha, and TNF-alpha through nucleotide-binding oligomerization domain 2-mediated signaling in osteoblasts.
    Yang S; Takahashi N; Yamashita T; Sato N; Takahashi M; Mogi M; Uematsu T; Kobayashi Y; Nakamichi Y; Takeda K; Akira S; Takada H; Udagawa N; Furusawa K
    J Immunol; 2005 Aug; 175(3):1956-64. PubMed ID: 16034140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes.
    Sone S; Mutsuura S; Ogawara M; Tsubura E
    J Immunol; 1984 Apr; 132(4):2105-10. PubMed ID: 6699409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distribution and fate of free and liposome-encapsulated [3H]nor-muramyl dipeptide and [3H]muramyl tripeptide phosphatidylethanolamine in mice.
    Fogler WE; Wade R; Brundish DE; Fidler IJ
    J Immunol; 1985 Aug; 135(2):1372-7. PubMed ID: 4008926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The schistosomulicidal activity and the production of IL-1 and TNF-alpha by peritoneal macrophages from infected mice and their potentiation by muramyl tripeptide-phosphatidyl ethanolamine (MTP-PE) treatment.
    Seger M; Gold D; Lengy J; Pauli H; Keisari Y
    Parasite Immunol; 1993 Jun; 15(6):339-47. PubMed ID: 8361776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipopolysaccharide (LPS)- and muramyl dipeptide (MDP)-induced anorexia during refeeding following acute fasting: characterization of brain cytokine and neuropeptide systems mRNAs.
    Gayle D; Ilyin SE; Flynn MC; Plata-Salamán CR
    Brain Res; 1998 Jun; 795(1-2):77-86. PubMed ID: 9622598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
    Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N
    J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
    Kleinerman ES
    Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ.
    Pahl JH; Kwappenberg KM; Varypataki EM; Santos SJ; Kuijjer ML; Mohamed S; Wijnen JT; van Tol MJ; Cleton-Jansen AM; Egeler RM; Jiskoot W; Lankester AC; Schilham MW
    J Exp Clin Cancer Res; 2014 Mar; 33(1):27. PubMed ID: 24612598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial.
    Vail DM; MacEwen EG; Kurzman ID; Dubielzig RR; Helfand SC; Kisseberth WC; London CA; Obradovich JE; Madewell BR; Rodriguez CO
    Clin Cancer Res; 1995 Oct; 1(10):1165-70. PubMed ID: 9815908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Upregulation of interferon-induced indoleamine 2,3-dioxygenase in human macrophage cultures by lipopolysaccharide, muramyl tripeptide, and interleukin-1.
    Hissong BD; Byrne GI; Padilla ML; Carlin JM
    Cell Immunol; 1995 Feb; 160(2):264-9. PubMed ID: 7720088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Muramyl dipeptide and mononuclear cell supernatant induce Langhans-type cells from human monocytes.
    Mizuno K; Okamoto H; Horio T
    J Leukoc Biol; 2001 Sep; 70(3):386-94. PubMed ID: 11527988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells.
    Kurzman ID; Shi F; Vail DM; MacEwen EG
    Cancer Biother Radiopharm; 1999 Apr; 14(2):121-8. PubMed ID: 10850295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state.
    Sone S; Utsugi T; Tandon P; Ogawara M
    Cancer Immunol Immunother; 1986; 22(3):191-6. PubMed ID: 3731204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endotoxin and muramyl dipeptide modulate surface receptor expression on human mononuclear cells.
    Heinzelmann M; Polk HC; Chernobelsky A; Stites TP; Gordon LE
    Immunopharmacology; 2000 Jul; 48(2):117-28. PubMed ID: 10936509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bacterial lipopolysaccharide, phorbol myristate acetate, and muramyl dipeptide stimulate the expression of a human monocyte surface antigen, Mo3e.
    Todd RF; Alvarez PA; Brott DA; Liu DY
    J Immunol; 1985 Dec; 135(6):3869-77. PubMed ID: 3934269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Production and characterization of cytostatic protein factors released from human monocytes during exposure to lipopolysaccharide and muramyl dipeptide.
    Kildahl-Andersen O; Nissen-Meyer J
    Cell Immunol; 1985 Jul; 93(2):375-86. PubMed ID: 3873995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liposomes containing muramyl tripeptide phosphatidylethanolamine (MTP-PE) are excellent adjuvants for induction of an immune response to protein and tumor antigens.
    Ullrich SE; Fidler IJ
    J Leukoc Biol; 1992 Nov; 52(5):489-94. PubMed ID: 1431559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.